Sometimes advances in drug development are like London buses: you wait for ages, and then loads turn up at once. This has certainly been the case in the non-alcoholic steatohepatitis (NASH) space, with several mid-stage trials yielding positive – or positive-ish – data in the past few months.
Key Takeaways
- Madrigal’s resmetirom is likely to become the first drug approved in NASH later this year
But there is much more to come. Players including Novo Nordisk A/S, Boehringer Ingelheim GmbH, Pfizer Inc....
